Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sahm, Katharina [VerfasserIn]   i
 Bunse, Lukas [VerfasserIn]   i
 Mildenberger, Iris [VerfasserIn]   i
 Wick, Wolfgang [VerfasserIn]   i
 Platten, Michael [VerfasserIn]   i
Titel:Immuntherapien bei Gliomen
Paralleltitel:Glioma immunotherapy
Verf.angabe:Katharina Ochs, Lukas Bunse, Iris Mildenberger, Wolfgang Wick, Michael Platten
E-Jahr:2017
Jahr:13. Juli 2017
Umfang:7 S.
Fussnoten:Gesehen am 22.08.2018
Titel Quelle:Enthalten in: Der Onkologe
Ort Quelle:Berlin : Springer, 1996
Jahr Quelle:2017
Band/Heft Quelle:23(2017), 10, Seite 831-837
ISSN Quelle:1433-0415
Abstract:BackgroundImmunotherapeutic approaches for treatment of malignant gliomas aim at inducing effective anti-tumor immune responses while counteracting the immunosuppressive tumor microenvironment. Despite extensive preclinical and clinical research during the last decades, there are currently no approved immunotherapeutic drugs for primary brain tumors; however, neuro-oncoimmunology is currently experiencing major interest due to new diagnostic and targeted therapy options as well as due to promising results in systemic tumors.ObjectiveThis article provides an overview of current concepts for glioma immunotherapy and summarizes the results of available clinical trials.ResultsWhile first clinical experiences with the administration of immune checkpoint inhibitors for gliomas did not raise any safety concerns, the efficacy of immune checkpoint monotherapy for malignant gliomas appears to be limited in an unselected patient population. Clinical results on combination treatment, such as T cell-based therapy approaches with antigen-specific vaccinations are pending. This involves mostly peptide vaccines that are directed against tumor antigens in order to generate an effective and at the same time specific anti-tumor immune response. In addition to vaccines against individually variable antigens, recurrent neoepitopes are particularly suitable as a target of vaccination, such as a splice variant of the epidermal growth factor (EGFRvIII) occurring in glioblastomas and a point mutation occurring in diffuse gliomas in the gene of isocitrate dehydrogenase-1 (IDH1R132H).
DOI:doi:10.1007/s00761-017-0258-y
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00761-017-0258-y
 DOI: https://doi.org/10.1007/s00761-017-0258-y
Datenträger:Online-Ressource
Sprache:ger
Sach-SW:EGFRvIII
 Glioblastom
 Glioblastoma
 IDH1R132H vaccine
 IDH1R132H-Vakzin
 Immuncheckpointinhibitor
 Immune checkpoint inhibitor
 Neoepitop
 Neoepitope
K10plus-PPN:1580295851
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68297963   QR-Code
zum Seitenanfang